Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
myotonic dystrophy kinase
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "myotonic dystrophy kinase" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
0 Images
DNA, d(P-thio)([2′-O-(2-methoxyethyl)]m5rU-[2′-O-(2-methoxyethyl)]m5rC-(3′→4′)-[2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-mannofurano]m5C-(3′→4′)-[2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-mannofurano]m5C-G-A-A-T-G-T-m5C-m5C-(3′→4′)-[2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-mannofurano]G-(3′→4′)-[2′,5′-anhydro-6′-deoxy-4′-C-(hydroxymethyl)-α-L-mannofurano]A-[2′-O-(2-methoxyethyl)]m5rC-[2′-O-(2-methoxyethyl)]rA), sodium salt (1:15)
Synonyms: IONIS 598769 sodium; ISIS 598769 sodium
Cat. No.: HY-177454
CAS No.: 2763758-01-4
Research Areas:
Basivarsen linker is a linker used in HY-177452 Zeleciment basivarsen for coupling a TfR1-binding Fab Zeleciment (HY-P990780) and an antisense oligonucleotide. Zeleciment basivarsen is an antibody-oligonucleotide conjugate (AOC) designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).
Cat. No.: HY-111423
CAS No.: 2226507-05-5
Target:
Research Areas:
BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ). BDP8900 reduces substrate phosphorylation, leading to morphological changes, motility inhibition and invasiveness of cancer cells .
Target:
Research Areas:
(R)-BDP9066 is an isomer of BDP9066 and has lower activity compared to BDP9066. BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 is derived from patent WO2019034890A1 (E118) .
Cat. No.: HY-111424AR
CAS No.: 2284549-25-1
Research Areas:
(R)-BDP9066 (Standard) is the analytical standard of (R)-BDP9066 (HY-111424A). This product is intended for research and analytical applications. (R)-BDP9066 is an isomer of BDP9066 and has lower activity compared to BDP9066. BDP9066 is a potent inhibitor of myotonic dystrophy Kinase-related Cdc42-binding Kinase (MRCK). (R)-BDP9066 is derived from patent WO2019034890A1 (E118) .
Cat. No.: HY-147262
Research Areas:
Etedesiran is a component of the AOC drug Delpacibart etedesiran (HY-177565), formed by the reaction of an siRNA that induces cleavage of mRNA encoding myotonic dystrophy protein kinase (MTPK or DMPK) with SMCC linker (HY-42360). Etedesiran carries a maleimide group at its terminus, which can react with cysteine or lysine and is used for the synthesis of AOC drugs. Etedesiran is applicable to research related to myotonic dystrophy type 1 .
Cat. No.: HY-185929
CAS No.: 3055410-06-2
Target:
Research Areas:
Pinzodirsen delvopertide is a fully P-chiral isomer-modified peptide-oligonucleotide conjugate (POC) and a steric blocker targeting myotonic dystrophy protein kinase (DMPK). Pinzodirsen delvopertide is applicable to mechanism research on myotonic dystrophy-related targets .
Cat. No.: HY-P701817
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDC42BPA; myotonic dystrophy kinase-Related CDC42-Binding Protein kinase Alpha; CDC42 Binding Protein kinase Alpha; myotonic dystrophy kinase-Related CDC42-Binding kinase Alpha; Serine/Threonine-Protein kinase MRCK Alpha; myotonic dystrophy kinase-Related
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P810947
Synonyms: KIAA0451, CDC42BPA, Serine/threonine-protein kinase MRCK alpha, CDC42-binding protein kinase alpha, DMPK-like alpha, myotonic dystrophy kinase-related CDC42-binding kinase alpha, MRCK alpha, myotonic dystrophy protein kinase-like alpha
Cat. No.: HY-P702634
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: CDC42BPG; myotonic dystrophy Protein kinase-Like Alpha; CDC42 Binding Protein kinase Gamma; myotonic dystrophy Protein kinase-Like Gamma; DMPK2; Serine/Threonine-Protein kinase MRCK Gamma; MRCKgamma; DMPK-Like Gamma; Kappa-200; MRCK Gamma; HSMDPKIN; MRCKG
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P811207
Synonyms: KIAA1124, CDC42BPB, Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, DMPK-like beta, myotonic dystrophy kinase-related CDC42-binding kinase beta, CDC42BP-beta, MRCK beta, myotonic dystrophy protein kinase-like beta
Cat. No.: HY-P812039
Synonyms: KIAA0451, CDC42BPA, Serine/threonine-protein kinase MRCK alpha, CDC42-binding protein kinase alpha, DMPK-like alpha, myotonic dystrophy kinase-related CDC42-binding kinase alpha, MRCK alpha, myotonic dystrophy protein kinase-like alpha
Cat. No.: HY-P812039A
Synonyms: KIAA0451, CDC42BPA, Serine/threonine-protein kinase MRCK alpha, CDC42-binding protein kinase alpha, DMPK-like alpha, myotonic dystrophy kinase-related CDC42-binding kinase alpha, MRCK alpha, myotonic dystrophy protein kinase-like alpha
Cat. No.: HY-185928
CAS No.: 2659211-29-5
Target:
Research Areas:
Pinzodirsen (Compound ENTR-Oligo-0034) is a dystrophia myotonica protein kinase (DMPK) steric blocker. Pinzodirsen reduces the nuclear sequestration of toxic DMPK mRNA with splicing factors such as MBNL1 via steric blocking/relocation, or interferes with the secondary structure of CUG repeat RNA, instead of being cleaved by RNase H, thereby ameliorating systemic aberrant splicing in DM1. Pinzodirsen is applicable to the research of myotonic dystrophy .
Cat. No.: HY-111424R
CAS No.: 2226507-04-4
Research Areas:
BDP9066 (Standard) is the analytical standard of BDP9066 (HY-111424). This product is intended for research and analytical applications. BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding Kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on sKin cancer by reducing substrate phosphorylation.
Cat. No.: HY-P702635
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: CDC42BPB; CDC42-Binding Protein kinase Beta; CDC42 Binding Protein kinase Beta; CDC42BP-Beta; myotonic dystrophy kinase-Related CDC42-Binding kinase Beta; MRCK Beta; Serine/Threonine-Protein kinase MRCK Beta; CDC42-Binding Protein kinase Beta (DMPK-Like)
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P705758
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CDC42BPB; CDC42-Binding Protein kinase Beta; CDC42 Binding Protein kinase Beta; CDC42BP-Beta; myotonic dystrophy kinase-Related CDC42-Binding kinase Beta; MRCK Beta; Serine/Threonine-Protein kinase MRCK Beta; CDC42-Binding Protein kinase Beta (DMPK-Like)
Species:
Human
Source:
sf9 insect cells
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
